IMBRUVICA (ibrutinib) - Risk of Serious and Fatal Cardiac Arrhythmias or Cardiac Failure

Serious and fatal events of cardiac arrhythmia or cardiac failure have occurred in patients treated with IMBRUVICA.

New safety information - Product safety

IMBRUVICA (ibrutinib), 140 mg, 280 mg, 420 mg and 560 mg tablets, and 140 mg capsules

RA-64510